The Lancet study increases pressure on the FDA, which is dealing with allegations that it tried to squelch prescient warnings by its own drug-safety reviewers about the dangers of Vioxx and about the hazards of antidepressant use by children and teenagers.
Anderson wrote that he believes there is value in the company's drug pipeline but said it is likely to get lost in the negative Vioxx coverage.
Pfizer Inc., the maker of two competing prescription drugs that are in the same class as Vioxx -- Celebrex and Bextra -- also has launched a big ad campaign.
